文献速递类风湿关节炎脊柱关节炎

类风湿关节炎或银屑病关节炎患者使用JAK抑制剂与生物改善病情抗风湿药的癌症风险:一项全国真实世界队列研究

Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
PubMed 文献 · Ann Rheum Dis · 2023-03-03

基于瑞典风湿病质量登记处2016—2020年数据,纳入10447例类风湿关节炎和4443例银屑病关节炎患者,比较JAK抑制剂与TNF抑制剂等生物制剂起始治疗后的癌症风险。类风湿关节炎中JAK抑制剂组非黑色素瘤皮肤癌风险高于TNF抑制剂组(HR 1.39),其他癌症风险无显著升高。

要点

  • 类风湿关节炎中,JAK抑制剂组非黑色素瘤皮肤癌风险高于TNF抑制剂组,HR 1.39(95%CI 1.01至1.91)。
  • 治疗起始2年及以上时,类风湿关节炎中非黑色素瘤皮肤癌HR为2.12(95%CI 1.15至3.89)。
  • 银屑病关节炎中,JAK抑制剂组非黑色素瘤皮肤癌HR 2.1(95%CI 0.8至5.3),未达统计学显著。

核心结论

  • 在临床实践中,JAK抑制剂起始治疗者短期非黑色素瘤皮肤癌以外癌症风险不高于TNF抑制剂,但发现非黑色素瘤皮肤癌风险增加的证据。

研究设计与样本

  • 基于瑞典风湿病质量登记处前瞻性收集数据并链接包括癌症登记处在内的其他登记处的队列研究,纳入2016—2020年起始JAK抑制剂、TNF抑制剂或其他非TNF抑制剂生物改善病情抗风湿药治疗的类风湿关节炎或银屑病关节炎患者。

主要发现

  • 类风湿关节炎中,JAK抑制剂组非黑色素瘤皮肤癌以外癌症38例 vs TNF抑制剂组213例,总体HR 0.94(95%CI 0.65至1.38)。
  • 类风湿关节炎中,JAK抑制剂组非黑色素瘤皮肤癌59例 vs TNF抑制剂组189例,HR 1.39(95%CI 1.01至1.91)。
  • 类风湿关节炎中,治疗起始2年及以上时非黑色素瘤皮肤癌HR 2.12(95%CI 1.15至3.89)。
  • 银屑病关节炎中,JAK抑制剂组非黑色素瘤皮肤癌以外癌症5例 vs TNF抑制剂组73例,HR 1.9(95%CI 0.7至5.2)。
  • 银屑病关节炎中,JAK抑制剂组非黑色素瘤皮肤癌8例 vs TNF抑制剂组73例,HR 2.1(95%CI 0.8至5.3)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Assess cancer risks with Janus kinase inhibitors (JAKi) versus biological disease-modifying antirheumatic drugs (bDMARDs) in clinical practice. METHODS: Cohort study of patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) initiating treatment with JAKi, tumour necrosis factor inhibitors (TNFi) or other (non-TNFi) bDMARDs 2016-2020 using prospectively collected data from the Swedish Rheumatology Quality Register linked to other registers including the Cancer Register. We estimated incidence rates, and HRs via Cox regression, for all cancers excluding non-melanoma skin cancer (NMSC), and for individual cancer types including NMSC. RESULTS: We identified 10 447 patients with RA and 4443 patients with PsA who initiated treatment with JAKi, a non-TNFi bDMARD or a TNFi. Median follow-up times in RA were 1.95, 2.83 and 2.49 years, respectively. In RA, based on 38 incident cancers other than NMSC with JAKi vs 213 with TNFi the overall HR was 0.94 (95% CI 0.65 to 1.38). Based on 59 vs 189 incident NMSC, the HR was 1.39 (95% CI 1.01 to 1.91). At 2 or more years since treatment start, the HR for NMSC was 2.12 (95% CI 1.15 to 3.89). In PsA, based on 5 vs 73 incident cancers other than NMSC, and 8 vs 73 incident NMSC, the corresponding HRs were 1.9 (95% CI 0.7 to 5.2) and 2.1 (95% CI 0.8 to 5.3). CONCLUSION: In clinical practice, the short-term risk of cancer other than NMSC in individuals initiating treatment with JAKi is not higher than for TNFi, but we found evidence of increased risk for NMSC.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Huss V, Bower H, Hellgren K, et al. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Ann Rheum Dis. 2023. PMID: 36868796. doi:10.1136/ard-2022-223636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。